• Pande Made Desy Ratnasari Sekolah Tinggi Farmasi Mahaganesha
  • Tri Murti Andayani Fakultas Farmasi, Universitas Gadjah Mada
  • Dwi Endarti Fakultas Farmasi, Universitas Gadjah Mada
Keywords: type 2 DM, direct medical costs, antidiabetic, complication


Type 2 diabetes mellitus (T2DM) is a chronic disease that requires high costs for lifelong therapy. Direct medical costs associated with the cost of antidiabetic and complications. The aim of the study was to determine the difference in direct medical costs based on antidiabetic prescribed and complications. The study design was cross-sectional. Data was taken retrospectively based on medical records and financial data in September 2017 at Panembahan Senopati Hospital Bantul Yogyakarta. Subjects in this study were 200 patients with inclusion criteria were type 2 DM outpatient, aged ≥18 years and received routine antidiabetic at least 3 months before the study. Exclusion criteria are patients with pregnant or breastfeeding. Analysis of differences in direct medical costs based on antidiabetic prescribed and complications using the Kruskal Wallis while sociodemographic were reviewed descriptively. The results showed 48.5% of patients with type 2 DM received combination oral and insulin. The most common complication was macrovascular (19.5%). The average direct medical cost was Rp489.005.00. There is a difference in direct medical costs based on antidiabetic prescribed (p=0.000) and complications (p=0.000). Patients receiving combination with oral and insulin and patients with macrovascular and microvascular complications have the highest direct medical costs.   


American Diabetes Association, 2013, Economic Costs of Diabetes in the U.S. in 2012, Diabetes Care. 36(4):1033–46.

Prajapati VB, Blake R, Acharya LD, Seshadri S, 2015, Assessment of quality of life in type II diabetic patients using the modified diabetes quality of life (MDQoL)-17 questionnaire, Brazilian J Pharm Sci. 53(4):1–9.

Zhuo X, Zhang P, Hoerger TJ, 2013, Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications, Am J Prev Med. 45(3):253–61.

Eristina, Antadayani T, Oetari R, 2017, Direct medical cost and utility analysis of diabetics outpatient at Karanganyar public hospital Direct medical cost and utility analysis of diabetics outpatient at Karanganyar public hospital, IOP Conf Ser Mater Sci Eng. 259:1–7.

Acharya K, Shah K, Solanki N, Rana D, 2013, Evaluation of antidiabetic prescriptions , cost and adherence to treatment guidelines : A prospective , cross-sectional study at a tertiary care teaching hospital, J Basic Clin Pharm. 4(4):82–7.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al., 2015 Jan, Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care. 38(1):140–9.

Bakris G, Blonde L, Boulton A, de Groot M, Greene E, Henry R, et al., 2017, Standards of Medical Care In Diabetes 2017, J Clin Apllied Res Educ. 41(1):1–150.

Laelasari E, Sauriasari R, Banun A, 2017, Cost-Effectiveness Analysis of Insulin, Sulfonylurea, and Sulfonylurea – Metformin In Type 2 Diabetes Mellitus, Asian J Pharm Clin Res. 10(5):50–3.

Ng C, Toh M, Ko Y, Lee J, 2015, Direct Medical Cost of Type 2 Diabetes in Singapore, PLoS One. 10(3):1–11.

Cannon A, Handelsman Y, Heile M, Shannon M, 2018, Burden of Illness in Type 2 Diabetes Mellitus, J Manag Care Spec Pharm. 24(9):S5–13.

Silva E, Ferreira C, Pinho L, 2017, Risk factors and complications in type 2 diabetes outpatients, Rev Assoc Med Bras. 63(7):621–7.

Domeikiene A, Vaivadaite J, Ivanauskiene R, Padaiga Z, 2014, ScienceDirect Direct cost of patients with type 2 diabetes mellitus healthcare and its complications in Lithuania, Mediciana. :S4–6.

Cheng S, Wang C, Chen J, Ko Y, 2018, Healthcare costs and utilization of diabetes-related complications in Taiwan, Medicine (Baltimore). 97(31):1–7.

Wu H, Eggleston KN, Zhong J, Hu R, Wang C, Xie K, et al., 2018, How do type 2 diabetes mellitus (T2DM) -related complications and socioeconomic factors impact direct medical costs ? A cross-sectional study in rural Southeast China, BMJ Open. 8:1–11.

Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, et al., 2015, NIH Public Access, Am J Manag Care. 19(5):421–30.

Zoungas S, Woodward M, Li Q, Cooper ME, Hamet P, Harrap S, et al., 2014, Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes, Diabetologia. 57:2465–74.

Chakraborty N, Mandal AK, 2016, A Study on Complications of Type 2 Diabetes Mellitus in a Diabetes Clinic of a Tertiary Care Hospital, Kolkata, West Bengal, IOSR J Dent Med Sci. 15(1):29–33.

Prachi D, Chirag D, Aarti P, Desai S, 2015, A Drug Prescribing Pattern Study in Diabetes Mellitus : An Outpatient Study, J Pharm Sci Biosci Res. 5(1):115–8.

Faridah IN, Dewintasari V, 2017, Quality of Life Analysis In Diabetes Mellitus Type 2 Patients Using Monotherapy and Combination Treatment of Medicine, Indones J Pharm. 28(2):119.

Wu Y, Ding Y, Tanaka Y, Zhang W, 2014, Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention, Int J Med. 11(11):1185–200.

Dashputra A, Badwaik R, Borkar A, Date A, Kalnawat N, 2014, Pattern of Antidiabetic Drugs used in Outpatient and Hospitalized Patients in a Tertiary Health Institute of Central India, J Cont Med A Dent. 2(5):48–54.

Rhee SY, Chon S, Kwon MK, Park IB, Ahn KJ, Kim IJ, et al., 2011, Prevalence of Chronic Complications in Korean Patients with Type 2 Diabetes Mellitus Based on the Korean National Diabetes Program, Diabetes Metab J. 35(5):504.

Forbes JM, Cooper ME, 2013, Mechanisms of diabetic complications, Physiol Rev. 93:137–88.

Bagle TR, Vare VA, Nimgade A, Hire RC, Sharma Y, Kshirsagar P, 2017, Pharmacoeconomic evaluation in cost of illness in type 2 diabetes mellitus patients in a tertiary care hospital, Int J Basic Clin Pharmacol. 6(10):2334–42.

Kalkan A, Bodegard J, Sundström J, Svennblad B, Johan C, Nilsson P, et al., 2016, Increased healthcare utilization costs following initiation of insulin treatment in type 2 diabetes : A long-term follow-up in clinical practice, Prim Care Diabetes. :1–9.

Cases M, Casajuana M, Nadal J, Casellas A, Vinagre I, Mauricio D, et al., 2016, Direct medical costs attributable to type 2 diabetes mellitus : a population-based study in Catalonia , Spain, Eur J Heal Econ. 17:1001–10.

Ambianti N, Andayani TM, 2019, Analisis Biaya Penyakit Diabetes Perencanaan Pembiayaan Kesehatan Melitus Sebagai Pertimbangan, J Farm Galen. 5(1):73–83.

Al-maskari F, El-sadig M, Nagelkerke N, 2010, Assessment of the direct medical costs of diabetes mellitus and its complications in the United Arab Emirates, BMC Public Health. 10(679):1–10.

Vaag A, Lund S, 2012, Insulin initiation in patients with type 2 diabetes mellitus : treatment guidelines , clinical evidence and patterns of use of basal vs premixed insulin analogues, Eur J Endocrinol. 166:159–70.

Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Julie LL, et al., 2018, Direct Medical Costs of Type 2 Diabetes in France : An Insurance Claims Database Analysis, PharmacoEconomics - Open. 2(2):209–19.

Abougalambou S, Abougalambou A, Ahmed N, 2019, International Journal of Diabetes : Current Anti-Diabetic Medication Cost of Type 2 Diabetic Patients at Tertiary Center, Int J Diabetes Curr Res. 1(1):1–9.

Ulrich S, Holle R, Wacker M, Stark R, Icks A, Thorand B, et al., 2016, Cost burden of type 2 diabetes in Germany: results from the population-based KORA studies, BMJ Open. 6(11):e012527.

Haghighatpanah M, Thunga G, Jha A, Mallayasamy S, 2016, Study on Prescribing Pattern of Anti Diabetic Drugs Among Type 2 Diabetes Patients With Complication In South Indian Teaching Hospital, Asian J Pharm Clin Res. 9(1):1–4.

Jabbar A, Abdallah K, Hassoun A, Malek R, Senyucel C, Spaepen E, et al., 2019, Patterns and trends in insulin initiation and intensification among patients with Type 2 diabetes mellitus in the Middle East and North Africa region, Diabetes Res Clin Pract. 149:18–26.

Pandit A, 2016, Comparative Effectiveness of Multi Oral Antidiabetic Drugs Versus Insulin Therapy For Glycemic Control In Type 2 Diabetes Mellitus, Asian J Pharm Clin Res. 9(1):262–4.

Mustapha FI, Azmi S, Rizal M, Manaf A, Hussein Z, Jasmin N, et al., 2017, What are the direct medical costs of managing Type 2 Diabetes Mellitus in Malaysia ?, Med J Malaysia. 72(5):271–7.

Vupputuri S, Kimes TM, Calloway MO, Christian JB, Bruhn D, Martin AA, et al., 2014, The economic burden of progressive chronic kidney disease among patients with type 2 diabetes, J Diabetes Complications. 28(1):10–6.

How to Cite
Ratnasari P, Andayani T, Endarti D. ANALISIS PERBEDAAN BIAYA MEDIK LANGSUNG PASIEN DIABETES MELITUS TIPE 2. JIFI [Internet]. 28Dec.2019 [cited 9Jul.2020];2(2):156-65. Available from:[]=414